{"name":"Elcelyx Therapeutics, Inc.","slug":"elcelyx-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Met DR","genericName":"Met DR","slug":"met-dr","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Met IR","genericName":"Met IR","slug":"met-ir","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Met DR","genericName":"Met DR","slug":"met-dr","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Met IR","genericName":"Met IR","slug":"met-ir","phase":"marketed","mechanism":"Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-10","type":"pipeline","source":"The Manila Times","summary":"MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - The Manila Times","headline":"MBX Biosciences Appoints Karen Basbaum as Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZG02U0d6RTVRSW92andJRkl2T0VfajNaNjVJekttbnFRX3BRZWwxVFd4anNKRTVlUHJSSUpfbHlVMjVvYlpteXVaMDBfMDZJYjVGdVc0NkZ1NXZxcVF6YlFWT1pxcjlBNVBUaE5tYklFSGdkb2xobmtmbU9aS2JzOFRjZVdfckNRTDkxU3ZhMDBZTXhGczM4OHZXT2pNN3ZmdEZrYzVxb2JUdzJKeUgwQ1ByOHVtRDJiajNVNw?oc=5","date":"2021-09-28","type":"pipeline","source":"Fierce Biotech","summary":"Anji Pharma nabs $70M for late-stage diabetes treatment, ex-Novartis asset - Fierce Biotech","headline":"Anji Pharma nabs $70M for late-stage diabetes treatment, ex-Novartis asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPLWxzY0xERU1tVjFpVHFHNG5ONllkVFpNQXk0R0t4VmsyaWotUWtmanVMZjhILW1ZSjFEcWt6Um9NX2hENF9XQlk1aUJiYjJZeW9OMTNwOXZoV0xkdm9KT2ROYmYzNXJzYmhuTmlUN1llcFRvVXJnbmxxM2o1cDA0WUJHdzF5Z051bEJwNEFaQ09SWXNfXzNvWnVlckZlT213Zm1waEJVaGtQVzRZcGdZ?oc=5","date":"2021-09-28","type":"trial","source":"MedCity News","summary":"Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model - MedCity News","headline":"Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBjN3RoYXpoTFJKcEg5YmlDVlNaelJ0bmpJOGpHMnZTdEx0eVJxNDhjMHNvR2NneWFuSWJHUjBZNkdlQ2ZhUFg2bThBZ3RuOWVhenFnYTQ3c1ZRS0pfOW1ZMW9ycw?oc=5","date":"2017-10-14","type":"pipeline","source":"colorado.edu","summary":"Ginger L. Graham - colorado.edu","headline":"Ginger L. Graham","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE81dTR4MnQ0M3FmRDc0dWFiVzhXVFZJUlNBb2RVb3pkbzBUOTd5Z0FMNVBKTktUYlRZS2FkZ2dLRndRMUZsczZfOHhkOWd4RFN3Z0M4Zl9HVFMwaGNUV0hSdzV0ZWdTckMxYWR3WDZCLTBma29T?oc=5","date":"2017-10-13","type":"pipeline","source":"colorado.edu","summary":"Ralph E. (Chris) Christoffersen - colorado.edu","headline":"Ralph E. (Chris) Christoffersen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}